Debut
Debut Biotechnology is a San Diego-based biotech company that uses its proprietary BeautyORB AI genomics platform and biomanufacturing to discover, validate, and supply novel clinically-validated beauty ingredients to B2B beauty brands, conglomerates (e.g., L'Oréal, Natura, Oterra), and consumers via its DEINDE brand.
- Company typePrivate
- Founded2019
- HeadquartersSan Diego, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Debut does
Debut Biotechnology, Inc. is a San Diego-based, venture-backed biotech beauty company founded in 2019 by Dr. Joshua Britton that combines AI-driven genomics with synthetic biology to discover, manufacture, and commercialize novel, clinically-validated beauty ingredients. The core technology is BeautyORB, a proprietary AI platform trained on 2B+ proprietary skin-health genomic data points that screens 96B+ ingredient possibilities and evaluates 30K genes, 20K molecules per minute, and 200+ biological pathways per discovery cycle. Debut couples BeautyORB to a vertically integrated stack of cell-free biomanufacturing, plant cell biotechnology, and precision fermentation, enabling it to produce rare, agriculturally constrained, or petrochemical-derived ingredients (e.g., Orris fragrance, bio-carmine red pigment, Red 40 food dye alternative) and four commercially launched DermCeutical skincare actives (NAR, DHK, EDL, PNar) targeting the 14 hallmarks of aging.
Debut operates a multi-stream business model. It sells proprietary cosmetic ingredients directly to beauty brands on a quote-based B2B basis (FCA San Diego), offers formulation and contract manufacturing services to beauty brands via the BiotechXBeautyLabs CMO (white-label in ~3 months, custom in ~7 months, no upfront R&D cost, 7,000+ proprietary claims, 95% bio-based formulations), and runs multi-year strategic co-development and supply partnerships with major consumer-goods companies — most notably L'Oréal (a dozen+ bio-identical ingredients), Natura (Latin American skin longevity), and Oterra (food colorants). Distribution is augmented by a wholly-owned consumer sub-brand, DEINDE, which functions as a proof-of-concept for biotech-derived ingredients. Go-to-market is enterprise-led (flagship conglomerate partnerships), supplemented by a B2B brand-partner channel (Formula Fig, Image Skincare) and a CMO/contract-manufacturing channel (KDC/one).
Debut is a Delaware-incorporated private company headquartered in San Diego with disclosed offices/facilities in San Diego, Atlanta (manufacturing), Singapore (regional HQ planned for Asia), and São Paulo (Latin America via Natura). It has raised ~$87M+ in disclosed funding across seed, Series A ($22.6M, 2021, Material Impact-led), Series B ($40M+, 2023, L'Oréal BOLD-led), and a 2025 $20M EDBI/BOLD round, and was named to the TIME100 Most Influential Companies 2025.
Debut firmographics
Firmographics- Name
- Debut
- Legal name
- Debut Biotechnology, Inc.
- Website
- https://debutbiotech.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Debut Biotechnology is a San Diego-based biotech company that uses its proprietary BeautyORB AI genomics platform and biomanufacturing to discover, validate, and supply novel clinically-validated beauty ingredients to B2B beauty brands, conglomerates (e.g., L'Oréal, Natura, Oterra), and consumers via its DEINDE brand.
- Ownership category
- akta.pro rank
Debut industry classification
Industry- Product category
- Biotech Cosmetic Ingredients
- NAICS
- Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Synthetic Dye and Pigment Manufacturing (32513)
- SIC
- Perfumes, Cosmetics & Other Toilet Preparations (2844), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Ingredient Blends & Systems / Custom Formulation (Seasoning Systems, Functional Blends) (CRADAOAO)
- akta.pro secondary industries
- Condition-Specific Bioactives (Glucosamine/Chondroitin, Plant Sterols, Melatonin, Lutein/Zeaxanthin) (AFAJAKAK), Bio-based Food & Flavor Ingredients (Non-fuel Co-products: sweeteners, organic acids, flavors) (EUAAAIAJ)
Keywords
Where Debut is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Debut business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- B2B Cosmetic Ingredient Sales: Direct sale of proprietary cosmetic ingredients (e.g., DermCeutical NAR, DHK, EDL, PNar) to beauty brand customers on a per-order basis. Products shipped FCA San Diego; quoted prices fixed for 30 days from quotation; lead times up to ~20 weeks for orders of 10kg or more.
- Contract Manufacturing (CMO) and Formulation Services: BiotechXBeautyLabs provides formulation development and contract manufacturing to beauty brands, with white-label products in as little as 3 months or custom formulations in 7 months. Includes access to 7,000+ proprietary claims and 95% bio-based formulations. Service revenue tied to formulation/CMO engagements.
- Strategic Ingredient Development Partnerships (L'Oréal, Oterra, Natura): Multi-year strategic co-development partnerships with major consumer goods companies (L'Oréal to develop a dozen+ bio-identical ingredients; Oterra for Red 40 alternative; Natura for AI-discovered skin longevity ingredient for Latin America). Revenue model is contract-based R&D and supply agreements.
- Direct-to-Consumer Brand (DEINDE): Consumer brand 'DEINDE' launched in 2024 as a biotech beauty proof-of-concept, including products such as the Radiance-Restoring Overnight Mask and the Overnight-Sculpting Face Tape. Generates retail/consumer revenue and serves as a validation platform for Debut's proprietary ingredients.
- B2B Brand Partnerships (e.g., Image Skincare): Debut partners with skincare brands such as Image Skincare to launch products using its proprietary ingredients (e.g., EDL skin-tightening). Brand partners sell finished products; Debut earns ingredient supply revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Quote-based B2B ingredient pricing (per kg, FCA San Diego) |
| Other | Multi-year contract | BiotechXBeautyLabs CMO/Formulation: project-based, no upfront R&D cost to brand |
Go-to-market motion4 records
Distribution channels6 records
Marketing channels8 records
Debut product offering
Product offeringCore offering
Debut combines AI-driven ingredient discovery with cell-free biomanufacturing, plant cell biotechnology, and precision fermentation to develop high-performance cosmetic ingredients (DermCeutical NAR, DHK, EDL, PNar), fragrance ingredients (Orris), and natural colorants (Bio-Carmine and a Red 40 alternative) for beauty and personal care brands. The company also operates BiotechXBeautyLabs, a formulation development and contract manufacturing service offering beauty brands white-label or custom biotech-enabled formulations with access to 7,000+ proprietary claims.
Product overview
Debut operates a vertically integrated platform-plus-modules architecture combining AI and biotechnology to discover, validate, and commercialize high-performance beauty ingredients. The core is the BeautyORB AI discovery platform, which screens 96 billion+ ingredient possibilities against 2 billion proprietary skin health data points and powers the development of all named DermCeutical ingredients (NAR, DHK, EDL, PNar) plus pipeline candidates (DBT-MH, DBT-PS, DBT-DDF, DBT-RR, DBT-NS, DBT-IC). The platform feeds into BiotechXBeautyLabs, the formulation development and contract manufacturing business unit that offers brands access to biotech ingredients via white-label or custom formulations. Debut's commercial ingredients include fragrance ingredients (Orris via plant cell biotechnology), colorants (Bio-Carmine and the Red 40 alternative with Oterra), and topical skin/hair care actives. DEINDE is Debut's own consumer skincare sub-brand serving as proof of concept. Debut also licenses technology and partners with L'Oréal, Natura, KDC/one, and Formula Fig for commercialization.
Differentiator
Problem solved
Functional benefit
Brands
- BiotechXBeautyLabs: Formulation development and contract manufacturing business launched in July 2024 giving beauty brands access to cutting-edge biotech ingredient and formulation innovation with no upfront research cost
- DEINDE
- BeautyORB
- DermCeutical
Products and services
- BeautyORB™ AI Ingredient Discovery Platform AI-powered genomics platform for skin health that screens 96 billion+ ingredient possibilities, leveraging 2 billion proprietary data points, 20,000 molecules screened per minute, and 200+ new pathways evaluated to discover novel, high-performance cosmetic ingredients.
- BiotechXBeautyLabs (CMO/Formulation Service) Formulation development and contract manufacturing business providing beauty brands access to biotech ingredients and custom formulations with no upfront research cost. White label products in ~3 months and custom formulations in ~7 months, with access to 7,000+ proprietary claims and 95% bio-based formulations.
- DermCeutical Naringenin (NAR) Topical skincare ingredient targeting anti-inflammaging; antioxidant that reduces inflammatory markers, strengthens the skin barrier, and scavenges reactive oxygen species. 15x better than niacinamide at reducing inflammaging markers; 100% saw improvement in elasticity and 97% saw improvement in wrinkles.
- DermCeutical DHK Topical skincare ingredient for skin barrier recovery; calms stressed skin, promotes repair, and preserves extracellular matrix integrity. Clinically designed for 2x faster barrier recovery; 81% saw improvement in overall skin appearance.
- DermCeutical EDL Topical skincare ingredient for skin tightening that activates autophagy to reduce sagging and restore a lifted appearance. 100% saw improvement in fine lines; 73% saw improvement in skin sagging; six-fold increase in elastin production in a 12-week study.
- DermCeutical PNar Topical skincare ingredient for hyperpigmentation that intercepts melanin production by blocking key enzymes including tyrosinase. 20.6% improvement in skin radiance after 12 weeks of twice-daily use; competes with kojic acid; EU regulatory compliant.
- Plant Cell Biotechnology Platform — Orris Fragrance Ingredient Plant cell biotechnology platform producing fragrance ingredients without traditional cultivation. Inaugural product is Orris (derived from iris root, valued up to $100,000/kg), which Debut can replicate in under one year versus a five-year traditional maturation cycle.
- Bio-Carmine Red Pigment First-ever molecular replica of the vibrant red pigment of carmine, produced via bioproduction as an animal-free alternative to carmine extracted from crushed insects. Targeted for use in food, beverage, and cosmetic applications.
- DEINDE Consumer Skincare Brand Consumer biotech skincare brand launched as a proof of concept for Debut's biotech-derived ingredients, backed by Debut's R&D and AI-driven molecule screening. Products include the Radiance-Restoring Overnight Mask and the Overnight-Sculpting Face Tape.
Quantifiable outcome
- EDL clinical study: 100% fine-line improvement rate; 73% skin sagging improvement; six-fold elastin production increase (12 weeks)
- +12 more outcomes
Companies that use Debut
Customer profileNamed customers7 records
Segments5 records
Ideal customer profiles5 records
Debut technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability9 records
Feature8 records
Debut partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered flagship and core.
- Natura (Natura Cosméticos S.A.)flagshipStrategic partnership to commercialize an AI-discovered skin longevity ingredient complex for the Latin American market. Combines Debut's BeautyORB AI platform (96B molecular possibilities) with Natura's two decades of Amazonian bioactives expertise and 46 socio-biodiversity ingredients. Partnership formalized with offices in San Diego and São Paulo. Products may launch as early as 2027.
- OterraflagshipMulti-million-dollar, multi-year (3-year) partnership to develop and scale a precision-fermented bio-based alternative to Red 40 food dye. Combines Debut's AI-powered biotech/precision fermentation with Oterra's 150-year heritage and formulation expertise in natural colors. FDA approval being pursued; targeting a $140M global market.
- Image SkincarecoreBrand partner launching a new skin-tightening product using Debut's proprietary EDL ingredient, scheduled for retail shelves in 2026.
- KDC/onecoreContract manufacturing partner for the launch of Debut's BeautyORB AI-powered ingredient discovery platform, enabling biotech innovation access for all beauty brands globally. KDC/one manufactures Debut's biotech ingredients for global commercialization.
- Formula FigcoreFirst professional channel partner signed by BiotechXBeautyLabs™. Collaboration to launch biotech-powered products in the professional beauty services market.
- U.S. Department of Defense (Defense Innovation Unit)coreDebut secured a major defense contract (per Fast Company coverage, August 2024). Details of the contract not specified in the source material.
- L'Oréal GroupeflagshipStrategic partnership to develop and scale biotech-derived ingredients that replace conventionally sourced components in beauty and personal care products. Scope includes more than a dozen synthetic bio-identical ingredients. Disclosed in July 2024 and reported as expanding the original 2023 L'Oréal investment partnership.
Scale indicators18 records
Recent moves10 records
Expansion highlights9 records
Debut competitors and assessment
Company assessmentDirect peers
- Checkerspot: Checkerspot uses microbial fermentation to produce novel oils and polyols for personal care, beauty, and lifestyle products, making it a directly comparable biotech ingredients platform serving overlapping beauty brand customers.
- Conagen: Conagen is a synthetic biology and precision fermentation company producing high-value ingredients for food, flavor, fragrance, beauty, and pharma — closely mirroring Debut's cell-free and precision fermentation approach to bio-based beauty and food colorant ingredients.
- Geltor: Geltor is an animal-free protein ingredient producer using synthetic biology for beauty and personal care; its fermentation-derived proteins address the same sustainability/ESG-driven replacement of animal-derived cosmetic ingredients that Debut's Bio-Carmine and bio-identical actives target.
- Amyris (ingredients business): Amyris pioneered synthetic biology-derived ingredients for beauty, fragrance, and personal care (e.g., squalane, BioE-Back), and remains the closest historical comp for a fermentation-driven beauty ingredients platform serving mass and prestige beauty brands.
Broad incumbents
- Givaudan: Givaudan is the world's largest fragrance and beauty ingredients house and is aggressively expanding into biotech/natural ingredients through its Active Beauty and microbiome platforms — competing with Debut for the same beauty conglomerate customers (L'Oréal, Natura) while offering a much broader portfolio.
- DSM-Firmenich: DSM-Firmenich is a global leader in flavors, fragrances, and beauty ingredients with active investments in biotech and fermentation-derived actives — a broad incumbent competitor to Debut across beauty, food, and nutrition ingredients.
- BASF (Care Chemicals division): BASF's Care Chemicals division supplies bio-based personal care and cosmetic ingredients globally with deep R&D and manufacturing scale; Debut's CSO and Sr. VP Processing both came from BASF/Verenium, underscoring the overlap in technology stack and customer base.
- IFF (Health & Biosciences): IFF's Health & Biosciences unit develops fermentation-derived ingredients for food, beverage, and personal care, directly comparable to Debut's precision fermentation and cell-free biomanufacturing programs (e.g., Red 40 alternative).
- Symrise: Symrise is a major flavors, fragrances, and cosmetic ingredients company investing in biotech and sustainable sourcing — overlapping with Debut's fragrance (Orris) and skincare active ingredients portfolios across global beauty conglomerate customers.
- Robertet: Robertet is a leading natural fragrance and flavor ingredients house with deep expertise in plant-derived and biotechnologically-produced aroma chemicals — comparable to Debut's plant cell biotechnology platform (e.g., Orris) and broader fragrance ingredient pipeline.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Debut social profiles
Digital presenceDebut compliance and trust
Trust signalCompliance1 record
Debut financial estimates
Financial estimateRevenue estimate
Valuation estimate
Debut leadership team
Management profileNumber of profiles
Profiles9 records
Debut subsidiaries and ownership
Company hierarchySubsidiaries3 records
Debut funding detail
Funding detailFunding overview
Funding rounds5 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Debut M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Debut
What does Debut do?
Debut combines AI-driven ingredient discovery with cell-free biomanufacturing, plant cell biotechnology, and precision fermentation to develop high-performance cosmetic ingredients (DermCeutical NAR, DHK, EDL, PNar), fragrance ingredients (Orris), and natural colorants (Bio-Carmine and a Red 40 alternative) for beauty and personal care brands. The company also operates BiotechXBeautyLabs, a formulation development and contract manufacturing service offering beauty brands white-label or custom biotech-enabled formulations with access to 7,000+ proprietary claims.
Is Debut a public or private company?
Debut is a private company. It is classified as venture growth investor backed and is currently operating.
When was Debut founded?
Debut was founded in 2019. It employs 51 to 100 people.
Where is Debut based?
Debut is headquartered in San Diego, United States, in the North America region.
How does Debut make money?
Five revenue lines are on record. B2B Cosmetic Ingredient Sales are the primary driver. The others are contract Manufacturing (CMO) and Formulation Services, strategic Ingredient Development Partnerships (L'Oréal, Oterra, Natura), direct-to-Consumer Brand (DEINDE) and B2B Brand Partnerships (e.g., Image Skincare).
Who are Debut's main competitors?
Direct peers on record are Checkerspot, Conagen, Geltor and Amyris (ingredients business). Broad incumbents are Givaudan, DSM-Firmenich, BASF (Care Chemicals division), IFF (Health & Biosciences), Symrise and Robertet.
Does Debut have an API?
No public API is recorded for Debut.
What industry is Debut in?
Debut's product category is Biotech Cosmetic Ingredients. Its primary akta.pro industry code is CRADAOAO, Ingredient Blends & Systems / Custom Formulation (Seasoning Systems, Functional Blends), with a secondary code of AFAJAKAK, Condition-Specific Bioactives (Glucosamine/Chondroitin, Plant Sterols, Melatonin, Lutein/Zeaxanthin). Its NAICS code is 325411 and its SIC code is 2844.